Regeneron is a leading biotechnology company that invents life-transforming medicines for people with serious diseases.

Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops, and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, Regeneron’s unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in Regeneron’s laboratories. Regeneron’s medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases.

Leadership Team

- **Leonard S. Schleifer, MD, PhD**
  Board co-Chair, co-Founder, President and Chief Executive Officer
  + Fellow, American Association for the Advancement of Science (AAAS)

- **George D. Yancopoulos, MD, PhD**
  Board co-Chair, co-Founder, President and Chief Scientific Officer
  + Member, National Academy of Sciences

- **Christine A. Poon**
  Lead Independent Director
  Former Vice Chair, Worldwide Chair of Pharmaceuticals, Member of the Executive Committee and Director at Johnson & Johnson

Board of Directors includes two Nobel Laureates and six members of the National Academy of Sciences

Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our proprietary technologies, such as VelociSuite®, which produces optimized fully human antibodies and new classes of bispecific antibodies. We are shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center® and pioneering genetic medicine platforms, enabling us to identify innovative targets and complementary approaches to potentially treat or cure diseases.

For more information, please visit [www.Regeneron.com](http://www.Regeneron.com) or follow Regeneron on [LinkedIn](https://www.linkedin.com/company/regeneron-pharmaceuticals), [Instagram](https://www.instagram.com/regeneron/?hl=en), [Facebook](https://www.facebook.com/Regeneron/) or [X](https://twitter.com/Regeneron)

General Company Information

- Founded in 1988: Publicly traded company (NASDAQ: REGN) since 1991
- More than 13,400 employees in the U.S., Canada, UK, EU and Asia
- 2023 R&D investment of $4.4 billion

Locations

- Tarrytown, NY: Corporate and Research & Development headquarters
- Dublin, Ireland: European headquarters
- Rensselaer, NY and Limerick, Ireland: Industrial Operations and Product Supply facilities
- U.S. offices in New York, New Jersey, Washington, D.C., Massachusetts and California
- Global offices in Canada, Netherlands, United Kingdom, Germany, France, Italy, Spain, Switzerland, India, Japan

FDA-Approved & Marketed Medicines*

- [Eylea® HD](#)
  ( aflibercept injection)
- [Eylea®](#)
  ( aflibercept injection)
- [Dupixent®](#)
  ( dupilumab injection)
- [Evkeeza®](#)
  ( evinacumab-drgb injection)
- [Arcalyst®](#)
  ( talsofivirus injection)
- [Inmazeb®](#)
  ( natalizumab, rituximab, and leflunomide injection)
- [KEVZARA®](#)
  ( sarilumab injection)
- [Liptay®](#)
  ( patisiran injection)
- [Praluent®](#)
  ( evolocumab injection)
- [Veopoz®](#)
  ( pozaramib-bbfg injection)
- [Zaltrap®](#)
  ( ziv-atiraxcept injection)

*Please see full Prescribing Information including Boxed WARNING for KEVZARA.

Please see full Prescribing Information including Boxed WARNING for Veopoz.

* U.S. Food and Drug Administration

---

- Commercialized by Kiniksa Pharmaceuticals, Ltd.
- Commercialized with Sanofi.
- Commercialized by Regeneron in the United States and Ultragenyx Pharmaceuticals Inc. outside the United States.
- Commercialized by Regeneron in the United States and Bayer outside the United States.
- Commercialized by Regeneron in the United States and Sanofi outside the United States.
- Commercialized by Sanofi.

*US.REGN.24.02.0001
Clinical Product Candidates

**PHASE 1**

- **MIVELSRAN**<br>RNAi therapeutic targeting APP<br>Early-onset Alzheimer’s disease
- **ALN-PNP**<br>RNAi therapeutic targeting PNP La3<br>NASH
- **DB-OTO**<br>AAV-based gene therapy<br>Hearing loss in pediatrics (Phase 1/2)
- **DUPILUMAB/LINVOSELTAMAB<br>Anti-body to IL-4R | Bispecific antibody targeting BCMA and CD3 | Severe food allergy**
- **FIANLIMAB**<br>Antibody to LAG-3 | Solid tumors, advanced hematologic malignancies
- **NTLA-2001**<br>TTR gene knockout using CRISPR/Cas9<br>Translational amyloidosis
- **ODRONETAMAB**<br>Bispecific antibody targeting CD20 and CD3<br>Certain B-cell malignancies
- **REGN4336**<br>Bispecific antibody targeting PSMA and CD3<br>Prostate cancer
- **DAVUTAMIG**<br>Bispecific antibody targeting two distinct MET epitopes<br>MET-altered advanced non-small cell lung cancer (NSCLC)
- **REGN5093-M114**<br>Bispecific antibody-drug conjugate targeting two distinct MET epitopes<br>MET overexpressing advanced cancer
- **REGN5381/REGN9035**<br>Antibody to aNFR1; Neutrophilic inflammatory diseases in Pediatrics

In collaboration with: Sanofi | Bayer | Intella | Ablynam

This graphic displays pipeline drug candidates currently undergoing clinical testing in a variety of diseases. The safety and efficacy of these drug candidates have not been fully evaluated by any regulatory authorities for the indications described in this section.

**PHASE 2**

- **REGN7075**<br>Bispecific antibody targeting EGFR and CD28<br>First-line advanced NSCLC (Phase 2/3; pivotal study)
- **ALN-APP**<br>RNAi therapeutic targeting APP<br>Cerebral amyloid angiopathy (CAA)
- **REGN5459**<br>Bispecific antibody targeting BCMA and CD3<br>Transplant desensitization in patients with chronic kidney disease
- **REGN5668**<br>Bispecific antibody targeting MUC16 and CD28<br>Platinum-resistant ovarian cancer
- **REGN6559**<br>Antibody to GPCR | Solid tumors
- **REGN7257**<br>Antibody to IL28b | Aplastic anemia
- **REGN7508**<br>Antibody to Factor XI | Thrombosis
- **REGN7999**<br>Antibody to TIMP3-SS6<br>Transfusion dependent iron overload
- **REGN5837**<br>Bispecific antibody targeting CD22 and CD28<br>Healthy volunteers
- **REGN7508**<br>Antibody to Factor XI | Thrombosis
- **REGN7544**<br>Next Generation Covid Antibody<br>Antibody to SARS-CoV-2 Variants
- **REGN7544**<br>Next Generation Covid Antibody<br>SARS-CoV-2 Variants
- **REGN7534**<br>Antibody to NFR1<br>Healthy volunteers
- **REGN13335**<br>Antibody to PDGF-B<br>Healthy volunteers
- **ODRONETAMAB**<br>Bispecific antibody targeting CD20 and CD3<br>Multiple myeloma
- **ORONETAMAB**<br>Bispecific antibody targeting CD20 and CD3<br>Multiple myeloma
- **LINVOSELTAMAB**<br>Bispecific antibody targeting BCMA and CD3<br>Multiple myeloma
- **LINVOSELTAMAB**<br>Bispecific antibody targeting BCMA and CD3<br>Multiple myeloma
- **FIVANLIMAB**<br>Bispecific antibody targeting LAG-3<br>First-line metastatic melanoma; First-line adjuvant melanoma
- **DUPILUMAB**<br>IL-4R Alpha Subunit Antibody<br>Chronic obstructive pulmonary disease (COPD); bullous pemphigoid; chronic spontaneous urticaria (CSU); chronic urticaria of unknown origin; asthma in pediatrics
- **FIANLIMAB**<br>Bispecific antibody targeting CD20 and CD3<br>Multiple myeloma
- **NEZAMOTIG (REGN5678)**<br>Bispecific antibody targeting PSMA and CD28<br>Prostate cancer
- **Trevogrumab (REGN10133)**<br>Antibody to Mesothelin (MCH2)<br>Healthy volunteers
- **ALN-HSD**<br>RNAi therapeutic targeting HDH1413 | NASH
- **CEMILIMAB**<br>Bispecific antibody targeting MUC16 and CD3<br>Metastatic NSCLC (Phase 2/3, pivotal study)
- **REGN8933**<br>Bispecific antibody targeting MUC16 and CD3<br>Multiple myeloma (Phase 2/3, pivotal study)
- **REGN10432**<br>Bispecific antibody targeting CD19 and CD3<br>Diffuse large B-cell lymphoma (DLBCL)
- **UBAMATAMAB**<br>Bispecific antibody targeting BCMA and CD3<br>Multiple myeloma (pivotal study; earlier; (pre)malignant multiple myeloma)

**PHASE 3**

- **EYLEA HD (AFLIBERCEPT) 8 MG**<br>VEGF | Renal vein occlusion (RVO)
- **CEMILIMAB**<br>Bispecific antibody targeting MUC16 and CD3<br>Metastatic NSCLC (Phase 2/3; pivotal study)
- **NIBILUMAB**<br>Anti-body to IL-4R<br>Chronic obstructive pulmonary disease (COPD); bullous pemphigoid; chronic spontaneous urticaria (CSU); chronic urticaria of unknown origin; asthma in pediatrics
- **NEZAMOTIG (REGN5678)**<br>Bispecific antibody targeting PSMA and CD28<br>Prostate cancer
- **ALN-HSD**<br>RNAi therapeutic targeting HDH1413 | NASH
- **CEMILIMAB**<br>Bispecific antibody targeting MUC16 and CD3<br>Metastatic NSCLC (Phase 2/3; pivotal study)
- **REGN8933**<br>Bispecific antibody targeting MUC16 and CD3<br>Multiple myeloma (Phase 2/3, pivotal study)
- **REGN10432**<br>Bispecific antibody targeting CD19 and CD3<br>Diffuse large B-cell lymphoma (DLBCL)
- **UBAMATAMAB**<br>Bispecific antibody targeting BCMA and CD3<br>Multiple myeloma (pivotal study; earlier; (pre)malignant multiple myeloma)

Leaders in Technology

- **Fully human monoclonal antibodies**
- **Genetic Medicine technology**
- **Regeneron Genetics Center®**

**Fully human monoclonal antibodies**
Regeneron has developed a suite of patented technologies (VelociSuite®), including VelociGene®, VelociImmune® and VelociMab®, that allow Regeneron scientists to determine the best targets for therapeutic intervention and rapidly generate high quality, fully human antibodies as drug candidates.

**Genetic Medicine technology**
We’ve made significant strides by leveraging our long-standing leadership in antibody technologies, combined with insights from the Regeneron Genetics Center® to build a pipeline of genetic medicine spanning multiple therapeutic approaches, including gene silencing, editing and gene therapy. With multiple genetic medicine-based technologies at our fingertips, we now have the potential to address the most promising genetic targets, driving forward scientific progress to change lives.

**Regeneron Genetics Center®**
A large-scale, fully-integrated genomics program that uses DNA sequencing and analysis to better understand the causes of disease, and to more rapidly and efficiently bring new therapeutics to patients in need.

LexisNexis: Innovation Momentum – The Global Top 100, 2024
Dow Jones Sustainability World Index; 2023
Dow Jones Sustainability North America Index, 2023
Human Rights Foundation: Corporate Equality Index, 2023
Science: Top Employer, 2023
Fast Company: Best Workplaces for Innovators, 2023
Forbes: America’s Best Employers for Women, 2023
Newsweek: America’s Greenest Companies, 2023

To learn more about us, please visit: REGENERON.COM